EntrepreneurialCheck
Osman Ozes estimated net worth profile

Osman Ozes net worth

Osman Ozes Net Worth 2026 (Estimated) · Founder at Altay Therapeutics · YC W20
est. wealth $15.0M

Quick answer

Osman Ozes's estimated net worth is $15.0M (range $10.5M – $22.5M) as of 2026. Osman Ozes is Founder at Altay Therapeutics. Altay Therapeutics valuation.

Osman Ozes is Founder at Altay Therapeutics (YC W20). Independent Entrepreneurial Check model estimate from public YC data.

At a glance

NameOsman Ozes
RoleFounder
CompanyAltay Therapeutics
YC batchW20
Est. company val$30.0M
Assumed ownership50%
Est. paper wealth / net worth$15.0M
$10.5M – $22.5M

Who is Osman Ozes?

Osman Ozes is a founder of Altay Therapeutics, which participated in Y Combinator's Winter 2020 batch.

Highlights:

  • Y Combinator (W20)
  • Altay Therapeutics

About Altay Therapeutics

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue.

With a team that has over 70+ years of small molecule drug...

FAQ: Osman Ozes net worth and Altay Therapeutics valuation

What is Osman Ozes's net worth?

Osman Ozes's estimated net worth is $15.0M (range $10.5M – $22.5M) as of 2026. Osman Ozes is Founder at Altay Therapeutics. Entrepreneurial Check publishes an independent model-based estimate from public company and role data. Not verified net worth, and Entrepreneurial Check is not affiliated with Y Combinator or the profiled companies.

What is Altay Therapeutics valuation?

Altay Therapeutics's estimated valuation on Entrepreneurial Check is $30.0M. That valuation, or a disclosed round when one is public, is the source for the paper-wealth estimate. Independent model output — not a verified appraisal or official mark.

What is Osman Ozes's role?

Osman Ozes is Founder at Altay Therapeutics, a Y Combinator-backed startup (batch W20).